PYC Therapeutics earns FDA orphan drug designation for RP11 therapy
PYC Therapeutics (ASX:PYC) has received Orphan Drug Designation from the US Food and Drug Administration for its drug candidate VP-001, aimed at treating Retinitis Pigmentosa type 11.
Read More